The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European specialty
AbbVie's recent acquisition of Nimble Therapeutics, a Roche spinout specializing in peptide-based oral drugs for immune diseases, represents a strategic move to enhance its already robust immunology pipeline. The $200 million deal is aimed at bolstering AbbVie's portfolio, particularly targeting
The Keck School of Medicine of USC has embarked on a groundbreaking research initiative aimed at addressing age-related cognitive decline in women. This significant effort is led by Dr. Young-Kwon Hong and has been bolstered by securing a $3.4 million federal grant from the Advanced Research
The field of drug discovery has long been hindered by the slow and laborious process of synthesizing and screening small molecules, putting a strain on scientific research advancements. Traditional methods are often time-consuming and require a high degree of specificity, making it difficult to
A significant advancement in hepatitis B vaccination has emerged, especially beneficial for individuals living with HIV. According to research led by a Weill Cornell Medicine investigator, a newer hepatitis B vaccine known as HepB-CpG (trade name Heplisav-B) demonstrates substantially superior
Alzheimer’s disease, a debilitating condition marked by progressive memory loss and cognitive decline, has long proven resistant to effective treatment, leaving millions of patients and their families searching for hope. Despite significant research efforts, traditional therapies targeting the